Sponsored – Est. Read 7 Min
Under-the-Radar Health Company Offers Disruptive Solution in a Booming Industry
PanGenomic Health (CSE: NARA) appears to be building the most scalable wellness platform in North America at precisely the right time.
A major health revolution is now underway in North America…and it’s triggering what could be an opportunity for potential windfall profits for early investors.
Here’s what’s happening:
The digital health market is absolutely exploding right now, with experts projecting that a $288 billion industry will more than triple in size by 2030.
As more people seek out smarter, faster and more personalized care – available in many cases right on their smartphone – they are using the power of technology to take charge of their own health choices.
At the same time, the health landscape is changing in a significant and powerful way, as Big Pharma’s era of control and influence over the FDA and Health Canada is ending. This has opened the door to more approved treatments in the natural health space.
As these two trends converge, PanGenomic Health Inc. (CSE: NARA) has emerged at the intersection and now offers investors a unique, early-stage opportunity in what is shaping up to be one of the most significant megatrends of our lifetime.
PanGenomic Health is developing an intelligent, AI-powered wellness ecosystem designed to help users take control of their physical and mental well-being with precision treatments rooted in natural medicine, genomics and diagnostic insights.
For investors, this represents tremendous opportunity, as PanGenomic Health remains under Wall Street’s radar with a market cap of just roughly $2 million CAD.
But the company’s platform is built to scale…it’s emerging in a leader in one of the fastest-growing sectors on the planet…and it’s all happening in the midst of a massive shift in consumer health trends.
As this high-upside scenario is now rapidly unfolding, I have summarized the most important points of the story below. Here now for you to consider are…
1
A Booming Market: Digital Health is Poised to Triple in Value
The global digital health market was worth $288 billion in 2024 and is projected to nearly triple by 2030, growing at more than 22% per year. At the same time, the medical AI market was estimated at $26.57 billion in 2024, as more people seek out smarter, faster and more personalized care. And right now mental health tech, digital diagnostics and natural treatment solutions are exploding in popularity. PanGenomic Health (CSE: NARA) is perfectly positioned at the intersection of all three of these trends, giving investors early-stage exposure to a megatrend that’s still in its formative stages.
2
America’s Changing Health Landscape Set to “Open the Floodgates”
Robert F. Kennedy Jr.’s “Make America Healthy Again” movement is expected to loosen Big Pharma’s grip on the FDA and open the floodgates for new, sanctioned alternative health research and treatments. These treatments will provide consumers with a myriad of new options, which means health professionals and patients will each need a trusted guide. That’s where PanGenomic Health’s AI-powered platform steps in as both an advisor and merchant, helping users cut through the noise and personalize their wellness journey in a meaningful way.
3
PanGenomic Health Offers a Fully Integrated Wellness Ecosystem
PanGenomic Health goes far beyond a single product…it’s an end-to-end platform connecting diagnostics, treatment, personalization and e-commerce into one seamless user experience. This powerful platform is built around the NARA app, which delivers natural treatment insights based on genetics, lifestyle data and AI to give users recommendations tailored to their personal biology. This ecosystem includes a variety of tools that work together to support both individuals and practitioners, a dual-channel approach designed to be both sticky and scalable.
4
PanGenomic’s Personalization Offers Precision Wellness
The company’s AI-powered platform is a fully integrated ecosystem of products that work together to deliver personalized, natural care…with AI and diagnostics driving smarter decisions every step of the way. This platform offers smart recommendations, real-time biomarker feedback an AI-powered product guidance. This type of hyper-personalized health – available at your fingertips – is the future of healthcare…and PanGenomic Health is building it now.
5
An Undervalued Opportunity in a Rapidly Growing Market
With a market cap of just roughly $2 million CAD, PanGenomic is still trading at a valuation well below its peers. Consider the valuations of other companies in the space such as AI/ML Innovations (CAD $15.6 million)… MindMed Inc. (US $588 million)…Teladoc Health, Inc. (US $1.2 billion)… and Hims & Hers Health, Inc. (US $11.9 billion). Compare these valuations to PanGenomic Health (CSE: NARA), which is trading at just a fraction of its peers and offers significant early-stage upside potential.
6
Backed by Experienced Leadership With a Track Record of Achieving Growth
PanGenomic Health is led by a proven, purpose-driven team that blends critical experience in biotech, AI and business. This impressive team includes CEO Maryam Marissen, a 20-year healthcare strategist with a passion for accessible wellness…CSO Kaidong Zhang, a diagnostics expert with deep scientific credibility…and Founders Robert Nygren and Vincent Lum, veteran tech and wellness entrepreneurs with the vision and track record to scale the NARA platform.
7
Catalyst-Rich Roadmap Offers the Potential for Strong Momentum
Because PanGenomic Health sits at the crossroads of AI and wellness, it’s exposed to multiple high-impact catalysts. Each new feature introduced can lead to added value, while expansion into new markets, product verticals or e-commerce growth could quickly attract investor attention. With so many potential catalysts and high scalability, each new milestone for the company has the potential to be significantly magnified in the market.
PanGenomic Health (CSE: NARA) Appears to Be a Hidden Gem in a Booming Industry
The global digital health market was estimated at $288 billion in 2024 and is expected to nearly triple by 2030, growing at a rate of more than 22% per year.
Wellness apps, AI diagnostic tools and natural treatment platforms are seeing record adoption as consumers now demand more personalized, holistic care.
At the same time, the AI-in-healthcare market was estimated at $26.57 billion in 2024 and is projected to grow at a CAGR of 38.62% per year from 2025 to 2030.[2]
This trend is accelerating as consumers seek out personalized alternatives to traditional healthcare.
“More than 70% of U.S. adults feel the health care system is failing to meet their needs in at least one way…(and) more than half of the adults surveyed graded the U.S. health care system a “C” or below.”
Simply put, there is tremendous frustration with the healthcare system in the United States…and with Big Pharma’s outsized influence over the FDA.
But that appears to be changing…and triggering an opportunity that PanGenomic Health (CSE: NARA) is perfectly positioned to pounce on.
Robert F. Kennedy Jr.’s “Make America Healthy Again” movement is seeking to radically reshape the U.S. healthcare system by allowing for more approved treatments in the natural health space.
This includes everything from peptides to psychedelics. And Big Pharma’s stranglehold on approved treatments could soon be fading.
This, of course, is likely to mean a wave of new demand for natural health treatments.
But it could also mean a great deal of confusion. What’s clear is that consumers will need trusted platforms to help guide their choices.
And that’s precisely what PanGenomic Health is building.
The Nara.AI Platform Offers Total Wellness Support in One Simple – Yet Powerful – Ecosystem
PanGenomic Health isn’t just a company looking to launch another health app.
Instead, the company’s Nara.AI platform is a fully integrated ecosystem of products that work together to deliver personalized, natural care…with AI and diagnostics driving smarter decisions every step of the way.
The NARA App is the heart of the platform.
NARA is a mental health app that curates natural remedies for individuals to manage and improve their mental wellness. With personalized insights and evidence-backed resources, users can take back control of their mental health.
The Nara.AI platform is designed to help individuals on their health journey by performing three critical tasks:
Task #1: Listen
A holistic approach to health and wellness requires listening to what the mind and body are saying. PanGenomic Health initially developed its NARA app as a mental health tool to curate evidence-based natural remedies for individuals seeking to improve their mental wellness.
The tool was based on pharmacogenomics, nutrigenomics and proteomics research data about natural remedies combined with an individual’s genomic and ongoing proteomic data.
The Nara.AI platform will leverage the NARA app by developing an individual user profile from their genome sequence plus protein and peptide profiles. PanGenomic’s Mujn diagnostic tools will then monitor by tracking changes in specific protein and peptide levels and other biomarkers.
Task #2: Recommend
The NARA app design recognizes that each person’s journey is unique and provides personalized insights into alternative health options based on customers’ medication, mood and biological factors.
As an educational platform, the app has a library of traditional and complementary medicines with scientifically supported information about benefits, dosage use, adverse effects, and drug interactions.
Harness the Power of Healing Insights
Nara is a mental health app that curates natural remedies for individuals to manage and improve their mental wellness. With personalized insights and evidence-backed resources, users can take back control of their mental health.
The Nara.AI platform will leverage the NARA app and Mujn diagnostic tools to make recommendation information available for the user or their health practitioner about personalized alternative health treatments, including initial dosages and dose changes from ongoing monitoring.
Task #3: Shop
The key strength of the Nara.AI platform will be its user-friendly e-commerce site designed to provide a tailored shopping experience for alternative health products.
Highly valuable and proprietary data from the Listen and Recommend features of the platform will be fed into the latest AI models and product sourcing engines to present the user with recommended purchases.
With the NARA app and the Nara.AI platform, PanGenomic cuts through the noise and provides insights that help people heal. The company’s platform delivers personalized natural remedy regimen options to help consumers and their healthcare practitioners support mental wellness.
Multiple Revenue Streams Help Prime PanGenomic Health (CSE: NARA) for Significant Potential Growth
The company’s e-commerce integration appears to be the key to its future growth.
As mentioned, based on data from the NARA app and diagnostic insights, users are guided to a tailored marketplace of natural health products matched to their unique profile.
It’s like having a personal wellness advisor, doctor and shop all in one place.
And the company has positioned itself to monetize multiple parts of the consumer’s wellness journey:
- E-commerce: PanGenomic Health’s largest future revenue stream will come from its AI-powered product recommendation engine. As users shop for supplements, peptides and wellness solutions, PanGenomic receives a portion of every transaction.
- App Subscriptions: Users pay to unlock advanced tools inside the NARA app, such as ongoing tracking, deeper insights and premium guidance.
- Diagnostic Tools: Through MUJN, PanGenomic Health will generate revenue by offering subscription and per-use pricing on its biomarker tracking hits.
Together, these revenue streams could create strong recurring revenue potential, especially as users return regularly for personalized products and updated recommendations.
BREAKING NEWS
PanGenomic Health Announces xxxxxxx xxxxxx xxxxxxxxx
On Month xx, 2025 PanGenomic Health Inc. (CSE: NARA) announced that it xxxxxx xxxxx xxxxxx xxxxxxx. On Month xx, 2025 PanGenomic Health Inc. (CSE: NARA) announced that it xxxxxx xxxxx xxxxxx xxxxxxx. On Month xx, 2025 PanGenomic Health Inc. (CSE: NARA) announced that it xxxxxx xxxxx xxxxxx xxxxxxx.
Compared to Industry Peers, PanGenomic Health (CSE: NARA) Appears to Have Room for Significant Potential Valuation Growth
To understand the potential that exists for investors with PanGenomic Health (CSE: NARA), let’s take a look at the company’s current status.
PanGenomic Health currently has a market cap of roughly $2 million CAD, which means it is trading at a valuation well below its peers.
The company currently has zero debt…under 7 million shares outstanding…and a product suite that compares favorably with companies that currently trade at valuations significantly higher than PanGenomic Health:
Even at a mere fraction of the 15x revenue multiple that HIMS currently trades for, PanGenomic Health (CSE: NARA) offers significant blue-sky potential. With its impressive, scalable AI-powered product suite – and its emphasis on a recurring e-commerce revenue stream – all of the pieces are in place for rapid growth potential.
An Experienced Leadership Team is Helping PanGenomic Health Execute its Vision
PanGenomic Health is led by an experienced team of founders, technology veterans and scientists with deep expertise in healthcare, AI and diagnostics.
This impressive team includes:
Maryam Marissen – CEO
Maryam has served in almost every facet of business — as a founder, board member, consultant, and now the CEO of PanGenomic. Her pursuit of excellence has pushed her to master a wide array of skill sets spanning consumer product marketing, private clinical services, public relations, and social advocacy, but the democratization of healthcare remains her primary mission.
Robert Nygren – Co-Founder, Executive Chair
Robert co-founded the biotech company Havn Life Sciences (CSE: HAVN) and served as a founding director of Psy Integrated Health Corp. He was also involved in establishing the Vancouver-based Empower Health clinic. In addition to these ventures, Robert co-founded the ETC3 Tech Centre located in the Research Campus of UBC. Prior to his involvement in these ventures, Robert served as the CEO of Epic Data and Fincentric.
Vincent Lum – Co-Founder, CEO, Director
Vincent has over 20 years of experience in the life sciences industry, where he has held several C-level positions. He is currently the CEO of MUJN Diagnostics. Vincent also co-founded Cardio-digital, which was later acquired by Medtronic. Prior to that, he served as Vice President and Partner at MDS Capital and Royal Bank Venture Capital.
Kaidong Zhang – Chief Science Officer
Kaidong has 15 years of experience in academia and industry, with a background in protein engineering and medicinal chemistry. His recent R&D projects include developing clinical diagnoses, managing chronic diseases with integrative medicine, developing nutraceutical products, and creating non-invasive diagnostic and therapeutic devices to manage chronic prostate disease and non-alcoholic fatty liver diseases.
The proven team leading the way for PanGenomic Health has the skillset, credibility and experience to build a meaningful AI-powered health platform.
Investor’s Summary:
PanGenomic Health (CSE: NARA) Offers a Smart, Scalable Wellness Play That Could Reward Early Investors
PanGenomic Health (CSE: NARA) is targeting the next major evolution in healthcare: smart, personalized, natural treatment delivered through the power of AI and digital diagnostics.
The company sits at the intersection of three high-growth trends:
1
The booming digital health market
2
Growing consumer demand for alternative and natural medicine
3
The rise of personalization through genomics and data.
With a comprehensive ecosystem that spans mental health, diagnostics, e-commerce and practitioner support – plus a low valuation relative to peers – the company appears to offer a compelling opportunity for early investors.
[1] https://www.grandviewresearch.com/industry-analysis/digital-health-market
[2] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market
[3] https://time.com/6279937/us-health-care-system-attitudes/
Full Disclaimer:
This website/newsletter is owned, operated and edited by Jade Cabbage Media LLC. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “Jade Cabbage” refers to Jade Cabbage Media LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and raise awareness for small public companies.
By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. The Jade Cabbage Media business model is to receive financial compensation to raise awareness for public companies.
Pursuant to an agreement between Winning Media LLC and the issuer, PanGenomic Health Inc. (NARA), Winning Media LLC has been hired for a period beginning on 6/23/25 and ending on 7/31/25 to conduct investor relations advertising and marketing and publicly disseminate information about PanGenomic Health Inc. (NARA) via Website, Email and SMS. Winning Media has been compensated the sum total of fifty thousand dollars via bank wire transfer. Furthermore, Winning Media LLC has paid up to fifteen thousand dollars to Jade Cabbage Media LLC to manage the production budget and digital media campaign for PanGenomic Health Inc. (NARA)
We expect to receive additional compensation as the investor awareness continues. We will disclose every amount we receive. We own zero shares of PanGenomic Health Inc. (NARA). This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only.
We have not investigated the background of the hiring party. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Jade Cabbage and Winning Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.